A Groundbreaking Study Awaits Your Participation!
For those navigating the maze of Alzheimer’s disease, it’s not just memory loss that’s a concern. Many patients with Alzheimer’s also face the challenges of psychosis – symptoms like hallucinations or delusions that can be deeply distressing. And for their families and caregivers, watching a loved one grapple with these symptoms can be heart-wrenching.
But what if there was a potential treatment on the horizon?
Introducing KarXT
KarXT is not just another medication; it’s a beacon of hope in the Alzheimer’s research community. It’s an innovative oral drug designed specifically to target and potentially alleviate the symptoms of psychosis seen in Alzheimer’s patients.
How Does KarXT Work?
This drug uniquely combines two components:
- Karbenzamine (Kar): It directly activates muscarinic receptors in the brain, which are vital for cognition, memory, and behavior. By stimulating these receptors, the goal is to reduce symptoms of psychosis.
- Xanomeline (XT): Previously developed for Alzheimer’s and schizophrenia, xanomeline had its challenges when used alone. However, in KarXT, it’s combined with Karbenzamine to limit those side effects.
In essence, KarXT offers the potential benefits of targeting psychosis-related receptors in the brain while minimizing side effects in other parts of the body.
Join the ADEPT-1 Study
The promise of KarXT is exhilarating, but it needs further evaluation, and this is where YOU come in.
We’re excited to introduce the ADEPT-1 study, a clinical trial designed to test the effectiveness and safety of KarXT for treating psychosis in Alzheimer’s patients. This is a pivotal moment in Alzheimer’s research, and it could potentially change the lives of countless individuals and their families.
Why Participate?
- Contribute to Scientific Advancement: Your participation can help push forward the boundaries of what we know about Alzheimer’s treatment.
- Potential Personal Benefit: While there’s no guarantee of personal benefit, participants in clinical trials often receive cutting-edge treatments before they’re widely available.
This study will be conducted as a Phase 3 randomized withdrawal study of KarXT in subjects with psychosis related to AD dementia. Subjects may or may not have symptoms of agitation.
Male and female subjects who are aged 55-90 years and have mild to severe AD dementia with moderate to severe psychosis will be enrolled.
The study includes an up to 30-day Screening Period, a 12-week Single-blind Treatment Period, a 26-week Double-blind Randomized Withdrawal Treatment Period, and a Safety Follow-up (SFU) visit following the end of treatment (EOT). The total duration of treatment is 38 weeks with a Screening Period and Safety Follow-up.
How to Get Involved
Do you or a loved one fit the bill? Are you driven to be a part of this groundbreaking research? If so, we urge you to reach out to our clinical research department. Even if you’re not sure about participation, a simple call can provide you with the information you need to make an informed decision.
You can also follow this link to get more information and see if you qualify.
Remember, every stride in medical research is made possible by the brave individuals and their families who step forward to participate. This is your chance to potentially make a massive difference in the world of Alzheimer’s treatment.
Take that step. Call our clinical research department today!
Note: Participation in clinical trials is voluntary. Always consult with healthcare professionals and understand the potential risks and benefits before deciding to join a study.